STAAR Surgical (NASDAQ:STAA) will be releasing its earnings data after the market closes on Thursday, February 21st.
Shares of NASDAQ:STAA opened at $36.75 on Thursday. The firm has a market cap of $1.50 billion, a PE ratio of 3,675.00 and a beta of 1.99. The company has a current ratio of 5.35, a quick ratio of 4.76 and a debt-to-equity ratio of 0.01. STAAR Surgical has a 52 week low of $13.60 and a 52 week high of $54.00.
A number of brokerages have recently commented on STAA. BidaskClub upgraded shares of STAAR Surgical from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 8th. Zacks Investment Research lowered shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday, November 7th. ValuEngine lowered shares of STAAR Surgical from a “strong-buy” rating to a “buy” rating in a report on Friday, December 21st. Finally, TheStreet lowered shares of STAAR Surgical from a “b-” rating to a “c” rating in a report on Friday, December 14th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. STAAR Surgical has a consensus rating of “Buy” and an average price target of $45.25.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by Modern Readers and is the sole property of of Modern Readers. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.modernreaders.com/news/2019/02/14/staar-surgical-staa-scheduled-to-post-quarterly-earnings-on-thursday.html.
STAAR Surgical Company Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
Featured Article: Benefits of owning preferred stock
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.